Informations:
Erreur:
ID
31007
Description
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin
Mots-clés
Versions (1)
- 10/07/2018 10/07/2018 -
Détendeur de droits
see clinicaltrials.gov
Téléchargé le
10 juillet 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755
Similar models
Patient Enrollment
- StudyEvent: ODM
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Body Weight
Item
Patient Body Weight
float
C0005910 (UMLS CUI [1])
Patient Height
Item
Patient Height
float
C0005890 (UMLS CUI [1])
Date of Birth
Item
Date of Birth
date
C0421451 (UMLS CUI [1])
CL Item
Male (1)
CL Item
Female (2)
Item Group
Lymphoid Neoplasms
C1518071 (UMLS CUI-1)
C0027627 (UMLS CUI-2)
C0027627 (UMLS CUI-2)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Leukemia, Prolymphocytic, B-Cell; Malignant lymphoma - lymphoplasmacytic; Lymphoma, Non-Hodgkin, Grade one rank; Lymphoma, Non-Hodgkin, Grade two rank; Aggressive Non-Hodgkin Lymphoma
Item
Does the patient have a histologically confirmed diagnosis of B-cell CLL/PLL/SLL; lymphoplasmacytic-immunocytoma; follicle center, follicular, grade I; or follicle center, follicular grade II non-Hodgkin's lymphoma or one of these B-cell lymphomas which has transformed to a more aggressive histology [according to Revised European-American classification of Lymphoid Neoplasms (REAL)]?
boolean
C1302547 (UMLS CUI [1])
C0475801 (UMLS CUI [2])
C0334633 (UMLS CUI [3])
C0024305 (UMLS CUI [4,1])
C0687695 (UMLS CUI [4,2])
C0024305 (UMLS CUI [5,1])
C0441802 (UMLS CUI [5,2])
C1332225 (UMLS CUI [6])
C0475801 (UMLS CUI [2])
C0334633 (UMLS CUI [3])
C0024305 (UMLS CUI [4,1])
C0687695 (UMLS CUI [4,2])
C0024305 (UMLS CUI [5,1])
C0441802 (UMLS CUI [5,2])
C1332225 (UMLS CUI [6])
Lymphoid Neoplasm Metastasis, Date of diagnosis
Item
Date of original diagnosis
date
C1518071 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C2316983 (UMLS CUI [1,3])
C0027627 (UMLS CUI [1,2])
C2316983 (UMLS CUI [1,3])
Item
REAL lymphoma histology at initial diagnosis
text
C1518071 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0008902 (UMLS CUI [1,3])
C1512888 (UMLS CUI [1,4])
C4071762 (UMLS CUI [1,5])
C0027627 (UMLS CUI [1,2])
C0008902 (UMLS CUI [1,3])
C1512888 (UMLS CUI [1,4])
C4071762 (UMLS CUI [1,5])
CL Item
B-cell CLL/PLL/SLL (B-cell CLL/PLL/SLL)
CL Item
lymphoplasmacytic-immunocytoma (lymphoplasmacytic-immunocytoma)
CL Item
follicle center, follicular, grade I (follicle center, follicular, grade I)
CL Item
follicle center, follicular, grade II (follicle center, follicular, grade II)
Lymphoid Neoplasm Metastasis, cell transformation
Item
Has transformation occurred?
boolean
C1518071 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0040682 (UMLS CUI [1,3])
C0027627 (UMLS CUI [1,2])
C0040682 (UMLS CUI [1,3])
Lymphoid Neoplasm Metastasis, cell transformation, Date in time
Item
Date of transformation
date
C1518071 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0040682 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,4])
C0027627 (UMLS CUI [1,2])
C0040682 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,4])
Item
Sites of disease at enrollment
text
C1518071 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C1515974 (UMLS CUI [1,3])
C1516879 (UMLS CUI [1,4])
C0027627 (UMLS CUI [1,2])
C1515974 (UMLS CUI [1,3])
C1516879 (UMLS CUI [1,4])
CL Item
Head (Head)
CL Item
Abdomen (Abdomen)
CL Item
Neck (Neck)
CL Item
Pelvis (Pelvis)
CL Item
Chest (Chest)
CL Item
Skin (Skin)
CL Item
Other (Other)
Antigens, Gene Expression, Tumor tissue sample, Evidence
Item
Does the patient have evidence that their tumor tissue expresses the CD20 antigen? Immunoperoxidase stains of paraffin embedded tissue showing positive reactivity with L26 antibody or immunoperoxidase stains of frozen tissue showing positive reativity with Anti-B1 Antibody (>50% of tumor cells are positive) or evidence of CD20 positivity by flow cytometry (>50% of tumor cells are positive) are acceptable evidence of CD20 positivity. Testing of tumor tissue from any time in the course of the patient's disease is acceptable.
boolean
C0054946 (UMLS CUI [1,1])
C0017262 (UMLS CUI [1,2])
C0475358 (UMLS CUI [1,3])
C3887511 (UMLS CUI [1,4])
C0017262 (UMLS CUI [1,2])
C0475358 (UMLS CUI [1,3])
C3887511 (UMLS CUI [1,4])
Prior Chemotherapy; Disease Progression
Item
Has the patient received 1 or 2 prior chemotherapy regimens and progressed following the last regimen? Patients who have received >2 prior chemotherapy regimens are excluded. Prior therapy with radiation, immunosuppressants, or steroids are not counted as chemotherapy regimens
boolean
C1514457 (UMLS CUI [1,1])
C0242656 (UMLS CUI [1,2])
C0242656 (UMLS CUI [1,2])
Item Group
Karnofsky Performance Status; Survival time, Anticipated
C0206065 (UMLS CUI-1)
C2919552 (UMLS CUI-2)
C3840775 (UMLS CUI-3)
C2919552 (UMLS CUI-2)
C3840775 (UMLS CUI-3)
Karnofsky Performance Status; Survival time, Anticipated
Item
Does the patient have a performance status of at least 60% on the Karnofsky Scale and an anticipated survival of at least 3 months?
boolean
C0206065 (UMLS CUI [1])
C2919552 (UMLS CUI [2,1])
C3840775 (UMLS CUI [2,2])
C2919552 (UMLS CUI [2,1])
C3840775 (UMLS CUI [2,2])
Item Group
ANC; Platelet Count
C0948762 (UMLS CUI-1)
C0032181 (UMLS CUI-2)
C0032181 (UMLS CUI-2)
ANC; Platelet Count
Item
Does the patient have an absolute granulocyte count (ANC) >1,500 cells x 10⁹/l and a platelet count >100,000 cells x 10⁹/l within 14 days of study entry? These blood counts must be sustained without support of hematopoietic cytokines or transfusion of blood products.
boolean
C0948762 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0032181 (UMLS CUI [2])
Absolute neutrophil count, Date in time; Platelet Count measurement, Date in time
Item
Date
date
C0948762 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
C0032181 (UMLS CUI [2,1])
C0011008 (UMLS CUI [2,2])
C0011008 (UMLS CUI [1,2])
C0032181 (UMLS CUI [2,1])
C0011008 (UMLS CUI [2,2])
ANC
Item
ANC
float
C0948762 (UMLS CUI [1])
Platelet count
Item
Platelet count
float
C0032181 (UMLS CUI [1])
Item Group
Renal function; Hepatic function
C0232804 (UMLS CUI-1)
C0232741 (UMLS CUI-2)
C0232741 (UMLS CUI-2)
Renal function; Hepatic function
Item
Does the patient have adequate renal function (defined as serum creatinine < 1,5 x upper limit of normal) and hepatic function [defined as total bilirubin < 1,5 x upper limit of normal and hepatic transaminases (AST + ALT) < 5 x upper limit of normal] within 14 days of study entry?
boolean
C0232804 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232741 (UMLS CUI [2])
undefined item
Item
text
Item Group
Bi-dimensionally measured disease
C1513041 (UMLS CUI-1)
C1705052 (UMLS CUI-2)
C1705052 (UMLS CUI-2)
Bi-dimensionally measured disease
Item
Does the patient have bi-dimensionally measured disease? At least one lesion must be ≥ 2 x 2 cm (by CT scan).
boolean
C1513041 (UMLS CUI [1,1])
C1705052 (UMLS CUI [1,2])
C1705052 (UMLS CUI [1,2])
Age
Item
Is the patient at least 18 years of age?
boolean
C0001779 (UMLS CUI [1])
Informed consent
Item
Has the patient signed the Ethics Committee-approved written informed consent form prior to study entry?
boolean
C0021430 (UMLS CUI [1])
Informed Consent Date
Item
Date consent signed
date
C2985782 (UMLS CUI [1])
Lymphoma, Bone Marrow
Item
Does the patient have an average of >25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens as assessed microscopically within 42 days of study entry? Bilateral posterior ilia crest biopsies are required if the percentage of intratrabecular space involved exceeds 10% on a unilateral biopsy. The mean of bilateral biopsies must be no more than 25%.
boolean
C0024299 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0005953 (UMLS CUI [1,2])
Prior Chemotherapy, Cytotoxic; Therapeutic radiology procedure, Before; Cytokine therapy, Before; Toxicity aspects
Item
Has the patient received cytotoxic chemotherapy, radiation therapy, or cytokine treatment within 4 weeks prior to study entry (six weeks for nitrosourea compounds) or exhibited persistent clinical evidence of toxicity? The use of systemic steroids must be discontinued 1 week prior to study entry.
boolean
C1514457 (UMLS CUI [1,1])
C0677881 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0199974 (UMLS CUI [3,1])
C0332152 (UMLS CUI [3,2])
C0040539 (UMLS CUI [4])
C0677881 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0199974 (UMLS CUI [3,1])
C0332152 (UMLS CUI [3,2])
C0040539 (UMLS CUI [4])
Hemopoietic stem cell transplant Following Chemotherapy Regimen; Hemopoietic stem cell transplant Following Therapeutic radiology procedure
Item
Has the patient undergone prior hematopoietic stem cell transplant following high dose chemotherapy or chemo/radiotherapy?
boolean
C0472699 (UMLS CUI [1,1])
C0332282 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
C0472699 (UMLS CUI [2,1])
C0332282 (UMLS CUI [2,2])
C1522449 (UMLS CUI [2,3])
C0332282 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
C0472699 (UMLS CUI [2,1])
C0332282 (UMLS CUI [2,2])
C1522449 (UMLS CUI [2,3])
Hydronephrosis, Obstructed, Active
Item
Does the patient have active obstructive hydronephrosis?
boolean
C0020295 (UMLS CUI [1,1])
C0549186 (UMLS CUI [1,2])
C0205177 (UMLS CUI [1,3])
C0549186 (UMLS CUI [1,2])
C0205177 (UMLS CUI [1,3])
Communicable Diseases; Antibiotics, Intravenous
Item
Does the patient have evidence of active infection requiring intravenous antibiotics at the time of study entry?
boolean
C0009450 (UMLS CUI [1,1])
C0003232 (UMLS CUI [1,2])
C0348016 (UMLS CUI [1,3])
C0003232 (UMLS CUI [1,2])
C0348016 (UMLS CUI [1,3])
New York Heart Association Classification; Illness, Serious
Item
Does the patient have New York Heart Association class III or IV heart disease or other serious illness that would preclude evaluation?
boolean
C1275491 (UMLS CUI [1])
C0221423 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C0221423 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
Malignant Neoplasms, Before
Item
Has the patient had prior malignancy other than lymphoma, except for adequately treated skin cancer, in-situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years?
boolean
C0006826 (UMLS CUI [1,1])
C0332152 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,2])
HIV infection
Item
Does the patient have known HIV infection?
boolean
C0019693 (UMLS CUI [1])
Metastatic malignant neoplasm to brain; Metastatic Malignant Neoplasm to the Leptomeninges
Item
Does the patient have known brain or leptomeningeal metastases?
boolean
C0220650 (UMLS CUI [1])
C1704231 (UMLS CUI [2])
C1704231 (UMLS CUI [2])
Pregnancy; Breast Feeding
Item
Is the patient pregnant or breast-feeding? Patients of childbearing potential must have a negative pregnancy test result within 7 days of study entry and radiolabeled antibody is not to be administered until a negative result is obtained.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Iodine, Allergic reaction
Item
Has the patient had previous allergic reaction to iodine (with the exception of reactions to intravenous iodine-containing contrast materials)?
boolean
C0021968 (UMLS CUI [1,1])
C1527304 (UMLS CUI [1,2])
C1527304 (UMLS CUI [1,2])
Monoclonal Antibodies; Polyclonal antibody
Item
Has the patient previously been given any monoclonal or polyclonal antibodies of any non-human species for either diagnostic or therapeutic purposes? This includes engineered chimeric and humanized antibodies.
boolean
C0003250 (UMLS CUI [1])
C0312586 (UMLS CUI [2])
C0312586 (UMLS CUI [2])
Radioimmunotherapy
Item
Has the patient previously received radioimmunotherapy?
boolean
C0085101 (UMLS CUI [1])
Progressive Neoplastic Disease, Response to treatment, Radiation Dosage
Item
Has the patient had progressive disease within one year of irradiation arising in a field that has been previously irradiated with > 3500 cGy?
boolean
C0677932 (UMLS CUI [1,1])
C0521982 (UMLS CUI [1,2])
C0034524 (UMLS CUI [1,3])
C0521982 (UMLS CUI [1,2])
C0034524 (UMLS CUI [1,3])
cancer treatment, Concurrent
Item
Is the patient concurrently receiving either approved or non-approved (through another protocol) anti-cancer drugs or biologics?
boolean
C0920425 (UMLS CUI [1,1])
C0205420 (UMLS CUI [1,2])
C0205420 (UMLS CUI [1,2])
Prior Chemotherapy
Item
Has the patient received >2 prior chemotherapy regimens? Prior therapy with radiation, immunosuppressants, or steroids are not counted as chemotherapy regimens.
boolean
C1514457 (UMLS CUI [1])